Article
Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Oncotarget - 26 Jan 2016
Penna Ilaria, Molla Alessandra, Grazia Giulia, Cleris Loredana, Nicolini Gabriella, Perrone Federica, Picciani Benedetta, Del Vecchio Michele, de Braud Filippo, Mortarini Roberta, Anichini Andrea
Abstract excerpt
Intrinsic cross-resistance to inhibition of different signaling pathways may hamper development of combinatorial treatments in melanoma, but the relative frequency of this phenotype and the strategies to overcome this hurdle remain poorly understood. Among 49 BRAF-mutant melanoma cell lines from...
Topics
- Animals
- Apoptosis
- Blotting, Western
- Cell Proliferation
- Drug Resistance, Neoplasm
- Female
- Humans
- MAP Kinase Kinase 1
- MAP Kinase Kinase 2
- Melanoma
- Mice
- Mice, SCID
- Mutation
- Phosphatidylinositol 3-Kinases